Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Depression
Phase NA
Enrollment 66
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Transcranial direct current stimulation (tDCS) is a neuromodulation method that modulates brain activity using low-intensity electrical current. Used in the treatment of depression, it is easily adaptable for both caregivers and patients, with good tolerance, under appropriate supervision. Allowing patients to perform tDCS at home could address issues of access to care (distance from home, overall cost of care, lack of healthcare professionals, difficulty travelling for physical/psychological reasons, etc.). Studies on tDCS have highlighted the importance of regular clinical monitoring to ensure compliance and safety, which are essential factors for therapeutic efficacy. The main objective of this study is to demonstrate the non-inferiority of tDCS performed at home versus in hospital in terms of effectiveness in reducing depressive symptoms at 6 weeks post-treatment in patients with moderate to severe depression.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: Distribution of study questionnaires — The questionnaires will be administered to patients at DO, D10, and M2. MADRS/RSES/EQ-5D-5L/BDI/CRQ
  • Other: tDCS sessions (D1-D10) — Protocol: 2 mA, 30 min, 10 working days (Monday to Friday), 2 sessions/day
  • Other: Monitoring tDCS appropriation — During visits to the hospital, the nurse ensures that the patient knows how to use the device correctly.
  • Other: Semi-structured interviews with patients — The interviews will be conducted by telephone with patients participating in the study. The purpose of these interviews is to gather information for the qualitative aspect of the implementation.

Primary Outcomes

  • Evaluate the non-inferiority of tDCS administered at home compared to in-hospital treatment in terms of effectiveness in reducing depressive symptoms 6 weeks post-treatment, using the MADRS (Montgomery-Asberg Depression Rating Scale). (2 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-31
Completion: 2028-03-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 66 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Nantes University Hospital
Collaborators: Direction Générale de l'Offre de Soins, Sooma Medical
Contact Information
Study Contact:
Damiens Choneau
02 53 48 28 35
bp-prom-regl@chu-nantes.fr
Christophe DAUDET
+33 5 59 52 33 00
cdaudet001@gmail.com
Clinique Mirambeau
Christophe DAUDET
Clinique Mirambeau
Interventions
  • Other: Distribution of study questionnaires — The questionnaires will be administered to patients at DO, D10, and M2. MADRS/RSES/EQ-5D-5L/BDI/CRQ
  • Other: tDCS sessions (D1-D10) — Protocol: 2 mA, 30 min, 10 working days (Monday to Friday), 2 sessions/day
  • Other: Monitoring tDCS appropriation — During visits to the hospital, the nurse ensures that the patient knows how to use the device correctly.
  • Other: Semi-structured interviews with patients — The interviews will be conducted by telephone with patients participating in the study. The purpose of these interviews is to gather information for the qualitative aspect of the implementation.
Study Locations (6 sites)
Clinique Mirambeau, Anglet, France
CH Georges Mazurelle, La Roche-sur-Yon, France
CHU de Nantes, Nantes, France
CHU de Nîmes, Nîmes, France
CH Le Rouvray, Sotteville-lès-Rouen, France
CH Léon-Jean Grégory - Thuir, Thuir, France
Eligibility Criteria
Inclusion Criteria: * Men or women over the age of 18 * Psychiatric diagnosis: * Presenting a depressive episode characterised according to DSM-5 criteria * MADRS score greater than or equal to 20, indicating moderate to severe depression * Indication and prescription of a course of tDCS treatment consisting of 20 sessions of 30 minutes at 2mA, at a rate of 2 sessions per day * Drug treatment: o Failure of a maximum of 1 or 2 antidepressants taken successively or in combination for the current episode * Psychiatric follow-up: Receiving medical follow-up by a psychiatrist or referring physician * Ability to understand and cooperate: * Having a smartphone, computer or tablet (with internet connection and Bluetooth) to use the digital interface required to perform remote tDCS * Be deemed capable of understanding the nature of the study and participating in clinical follow-up * Informed consent: Have given written consent to participate in the research, after receiving oral and written information about the study. * Social affiliation: Be affiliated with a social security system Exclusion Criteria: * Psychiatric or neurological diagnoses: * Chronic psychotic disorders or history of schizophrenia * Progressive neurological disorders (unstabilised epilepsy, brain tumour, recent stroke, severe head injury) * History or current treatment of neuromodulation * Any history of tDCS treatment, whether carried out in a clinical or research setting * Current treatment or history of rTMS and ECT sessions for the current episode * Presence of an active vagus nerve stimulation implant * Presence of a high risk of suicide. A risk of suicide will be considered high if the score on item 10 of the MADRS scale ("Suicidal Thoughts") is 4 or higher, and/or if there is active suicidal ideation accompanied by clinically identified intent or a plan * Addiction and substance use: Current substance use disorder other than nicotine or caffeine * Psychiatric comorbidities that may interfere with study participation, including: understanding information, adherence to the protocol, and completing CBT sessions. * Recent change in curative psychotropic treatment (antidepressant, mood stabiliser including lithium and anticonvulsants, mood-stabilising antipsychotic) in the month prior to inclusion. * Medical contraindication to stimulation: * Presence of a metallic or electronic implant in the skull or chest (pacemaker, neurostimulator, cochlear implant) * Skin lesion, irritation or wound on the electrode contact areas * History of epileptic seizures not related to an identified cause or not stabilised for more than 12 months * Current pregnancy or breastfeeding * Women of childbearing age without effective contraception (hormonal or medical device) * A severe and/or progressive somatic condition requiring ongoing medical care that would interfere with participation in the study. * Limited ability to participate: * A significant cognitive impairment or sensory deficit that prevents understanding of instructions * Inability to safely perform tDCS at home, as defined by at least one of the following: * inability to understand or recall essential instructions regarding procedure and safety; * inability to perform, following initial guidance, the essential steps for setting up and starting the device; * lack of the minimum material conditions required at home to conduct the sessions. * Special legal or social situation: * Patients under guardianship, curatorship or judicial protection * Privation of liberty by judicial or administrative decision, Presence of a functional limitation to the independent performance of tDCS
Conditions Anxiety Depression, Sleep
Phase PHASE4
Enrollment 180
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The main objective of this study is to compare medication (usual care; active comparator) with acupuncture (as experimental intervention) to identify the most (cost)effective and environmentally sustainable intervention to reduce depression, anxiety and comorbid sleep disorders in adults (18-65) in China.

Design

Study type: Interventional Phases: Phase4 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Drug: Psychotropic Drugs — 1. Trazodone (25-150 mg; once daily, 30 minutes before bedtime) or mirtazapine (3.75-30 mg; once daily, 30 minutes before bedtime) 2. Zopiclone (5-10 mg; once daily, taken at bedtime) or lorazepam (0.25-1 mg, once daily, taken at bedtime) Patients may also be prescribed 3. Escitalopram oxalate tablets (10-20 mg; once daily, 30 minutes after breakfast) in cases where Insomnia is Caused by Depressive and Anxious Symptoms The treatment is planned for 4 weeks. After 2 weeks, patients are invited for a check-in visit but there will be no change in the treatment prescribed for 4 weeks
  • Other: Acupuncture — Manual acupuncture (no sham) will be compared to medication. Acupuncture Points Selected: Bilateral Baihui (GV20), Yintang (GV29), Anmian (EX-HN22), Shenmen (HT7), Neiguan (PC6), Sanyinjiao (SP6), Zhaohai (KI6), Shenmai (BL62), and Taichong (LR3) (29, 30) Operational Procedure: 1. Patient Position: Supine position. 2. Needles: Single-use sterile needles (Specifications: 0.25 mm × 40 mm; Brand: Wuxi Jiajian). 3. Disinfection: Strict disinfection protocols must be performed prior to needling. 4. Needling Technique: After insertion, lifting-thrusting and twirling-rotating manipulation techniques are applied to elicit De Qi (the arrival of Qi). 5. Needle Retention Time: 20 minutes. 6. Treatment Regimen: * Frequency: 3 sessions per week (Monday, Wednesday, and Friday). * Course of Treatment: 9 to 10 sessions per course.

Primary Outcomes

  • Between-groups and within-subjects mean change in depression (Collected at baseline (T0) compared to post-treatment (T1), 3-months follow-up (T2) and 6-months follow-up (T3).)
  • Between-groups and within-subjects mean change in anxiety (Collected at baseline (T0) compared to post-treatment (T1), 3-months follow-up (T2) and 6-months follow-up (T3).)
  • Between-groups and within-subjects mean change in sleep condition (Collected at baseline (T0) compared to post-treatment (T1), 3-months follow-up (T2) and 6-months follow-up (T3).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2026-04-01
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Duke Kunshan University
Collaborators: Kunshan Hospital of Traditional Chinese Medicine, Kunshan Mental Health Center, National Natural Science Foundation of China
Principal Investigators:
  • Claudia Nisa (PRINCIPAL_INVESTIGATOR) - Duke Kunshan University
Contact Information
Study Contact:
Claudia F. Nisa
008618151144079
claudia.nisa@duke.edu
Interventions
  • Drug: Psychotropic Drugs — 1. Trazodone (25-150 mg; once daily, 30 minutes before bedtime) or mirtazapine (3.75-30 mg; once daily, 30 minutes before bedtime) 2. Zopiclone (5-10 mg; once daily, taken at bedtime) or lorazepam (0.25-1 mg, once daily, taken at bedtime) Patients may also be prescribed 3. Escitalopram oxalate tablets (10-20 mg; once daily, 30 minutes after breakfast) in cases where Insomnia is Caused by Depressive and Anxious Symptoms The treatment is planned for 4 weeks. After 2 weeks, patients are invited for a check-in visit but there will be no change in the treatment prescribed for 4 weeks
  • Other: Acupuncture — Manual acupuncture (no sham) will be compared to medication. Acupuncture Points Selected: Bilateral Baihui (GV20), Yintang (GV29), Anmian (EX-HN22), Shenmen (HT7), Neiguan (PC6), Sanyinjiao (SP6), Zhaohai (KI6), Shenmai (BL62), and Taichong (LR3) (29, 30) Operational Procedure: 1. Patient Position: Supine position. 2. Needles: Single-use sterile needles (Specifications: 0.25 mm × 40 mm; Brand: Wuxi Jiajian). 3. Disinfection: Strict disinfection protocols must be performed prior to needling. 4. Needling Technique: After insertion, lifting-thrusting and twirling-rotating manipulation techniques are applied to elicit De Qi (the arrival of Qi). 5. Needle Retention Time: 20 minutes. 6. Treatment Regimen: * Frequency: 3 sessions per week (Monday, Wednesday, and Friday). * Course of Treatment: 9 to 10 sessions per course.
Study Locations (1 sites)
Kunshan Mental Health Center and Kunshan Hospital of Traditional Chinese Medicine, Kunshan, Jiangsu China
Eligibility Criteria
Inclusion Criteria: 1. Chinese nationals 18-65 years old 2. At least one of the screening scores below suggestive of depression/anxiety tendencies: 1. Depressive state: Depression Self-Rating Scale (SDS) raw score ≥43; standard score ≥53 (27) 2. Anxiety state: Anxiety Self-Rating Scale (SAS) raw score ≥40; standard score ≥50 (28) Note: (standard score = raw score X 1.25) Exclusion Criteria: 1. Patients with severe comorbid physical illnesses that prevent them from completing the full course of treatment; 2. Patients with a risk of suicide; 3. Patients with a history of head trauma, loss of consciousness, or severe mental disorders; 4. Patients with drugs or alcohol abuse; 5. Patients who have received physical treatment methods within the past 3 months; 6. Patients who have received antidepressant or antipsychotic medication treatment within the past 3 months; 7. Patients with severe skin lesions or skin diseases.
Conditions Type 2 Diabetes Mellitus, T2DM
Phase PHASE2
Enrollment 180
Locations 15 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is a Phase 2 clinical trial to evaluate the efficacy, safety, and tolerability of HM15275 in subjects with type 2 diabetes mellitus over 36 weeks.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: HM15275 — HM15275 is a sterile solution for subcutaneous injection, supplied pre-filled syringes.
  • Drug: Placebo of HM15275 — A sterile, matching solution supplied in pre-filled syringes.

Primary Outcomes

  • Change in Glycated Hemoglobin (HbA1c) (Up to 41 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-05-18
Completion: 2027-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hanmi Pharmaceutical Company Limited
Contact Information
Study Contact:
Pureun Nam
+82-2-410-9147
pureun.nam@hanmi.co.kr
Hyeonho Choi
+82-2-410-9834
hyeonho.choi@hanmi.co.kr
Gerald Shockey
Desert Clinical Research
Interventions
  • Drug: HM15275 — HM15275 is a sterile solution for subcutaneous injection, supplied pre-filled syringes.
  • Drug: Placebo of HM15275 — A sterile, matching solution supplied in pre-filled syringes.
Study Locations (15 sites)
Desert Clinical Research, Mesa, Arizona 85123 United States
Accel Research Sites - DeLand, DeLand, Florida 32720 United States
Charter Research, Orlando, Florida 32803 United States
AdventHealth Translational Research Institute, Orlando, Florida 32804 United States
K2 Medical Research The Villages LLC, The Villages, Florida 32159 United States
Centricity Research IRT - DBA IACT Health Columbus Piedmont, Columbus, Georgia 31904 United States
The South Bend Clinic, South Bend, Indiana 46617 United States
Jefferson City Medical Center, Jefferson City, Missouri 65109 United States
Clay Platte Family Medicine, Kansas City, Missouri 64151 United States
Methodist Physicians Clinic, Fremont, Nebraska 68025 United States
Eligibility Criteria
Key Inclusion Criteria 1. Participant's age at the time of signing the informed consent: * United States: 18 to 75 years (inclusive) 2. Diagnosed with type 2 diabetes mellitus (T2DM) with HbA1c ≥7.0% and ≤10.0% at screening 3. Treated with diet and exercise alone or on a stable dose of metformin (≥1000 mg/day) for at least 3 months prior to screening 4. BMI ≥25 kg/m² and ≤50 kg/m² 5. Body weight change \<5% over the past 3 months prior to screening 6. Capable of giving signed informed consent and willing to comply with all protocol procedures Key Exclusion Criteria 1. Type 1 diabetes mellitus or use of glucose-lowering medications other than metformin within 3 months prior to screening 2. Poor glycemic control (fasting plasma glucose \>270 mg/dL) 3. History of diabetic ketoacidosis or severe hypoglycemia within 6 months 4. Clinically significant cardiovascular disease (e.g., NYHA class III/IV heart failure, recent myocardial infarction, stroke, or revascularization within 3 months) 5. History of pancreatitis or factors increasing the risk of pancreatitis 6. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 7. Clinically significant liver disease, renal impairment (eGFR \<60 mL/min/1.73 m²), or abnormal laboratory findings at screening 8. Participation in another investigational study within 30 days or within 5 half-lives of the investigational product, whichever is longer; for GLP-1 receptor agonist-related or weight loss studies, participation within 3 months prior to screening
Conditions Brain Metastases From Non-small Cell Lun...
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate the diagnostic potential of 68-Gallium PSMA-PET/CT in stereotactic irradiated brain metastases from non-small cell lung cancer, melanoma and breast cancer.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: 86-Gallium PSMA PET/CT — PET/CT 45 minutes after intravenous administration of 100MBq Gallium-68 labelled PSMA-11 (\[68Ga\]Ga-PSMA-11)

Primary Outcomes

  • Tracer Uptake (SUVpeak) on PSMA PET/CT in Brain Lesions (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2019-12-24
Completion: 2027-07-01
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Netherlands Cancer Institute
Principal Investigators:
  • Dieta Brandsma, MD, PhD (PRINCIPAL_INVESTIGATOR) - Antoni van Leeuwenhoek Ziekenhuis
Contact Information
Study Contact:
Lente Kroon, MD
0031205129111
neurologie@nki.nl
Dieta Brandsma, MD, PhD
Lente Kroon, MD
0205129111
neurologie@nki.nl
Netherlands Cancer Institute - Antoni van Leeuwenhoek
Interventions
  • Diagnostic Test: 86-Gallium PSMA PET/CT — PET/CT 45 minutes after intravenous administration of 100MBq Gallium-68 labelled PSMA-11 (\[68Ga\]Ga-PSMA-11)
Study Locations (1 sites)
Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, 1066 CX Amsterdam Netherlands
Eligibility Criteria
Inclusion Criteria: For all groups: * Written informed consent * Age ≥ 18 years old * WHO PS 0-3 * Measurable lesion ≥10mm according to RANO BM For brain metastases groups: \- newly diagnosed brain metastases from either NSCLC (group 1) or melanoma (group 2) or breast cancer (group 7). For radiation necrosis groups: \- Brain lesion at the location of a formerly brain metastases that has been treated with SRT (\> 9 months ago), with the definite diagnosis of radiation necrosis at the location of formerly SRT-treated brain metastases of NSCLC (group 3), melanoma (group 4) and/ or breast cancer (group 8). For diagnostic dilemma groups: \- Brain lesion at the location of a formerly brain metastases with a diagnostic dilemma of radiation necrosis and recurrent brain metastases of NSCLC (group 5), melanoma (group 6) and/ or breast cancer (group 9). Exclusion Criteria: For all groups: * Known allergy to Ga68-PSMA * Epileptic seizure less than 7 days before Ga68-PSMA PET/CT scan * Life expectancy less than 3 months * Patients with known prostate carcinoma * Pregnancy
Conditions Breast Diseases, Breast Neoplasms, Dalpi...
Phase PHASE2
Enrollment 2000
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is a multicenter, prospective, randomized, open-label clinical study to assess the efficacy and safety of endocrine combined with different doses and treatment duration of darisenatide adjuvant therapy in HR +/HER2- early breast cancer. The study planned to include 2000 HR +/HER2- early breast cancer patients who met the study criteria and were randomized in a 1:1 ratio to Column 1 and Column 2 stratified by nodal status (positive/negative), prior (neo) adjuvant chemotherapy (yes/no), and clinical/pathological stage (Stage II/III). Cohort 1 received dalcili 125 mg in combination with endocrine therapy for 2 years with dalcili; Cohort 2 received dalcili 100 mg in combination with endocrine therapy for 3 years with dalcili; treatment had to be discontinued until disease progression, intolerable adverse events, withdrawal of consent, or investigator judgment.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Dalpiciclib 125mg — Dalpiciclib: 125 mg, once daily, taken at approximately the same time every day, fasting 1 hour before and after taking the drug, for 21 consecutive days, followed by 7 days off, 28 days as a treatment cycle. It was administered for 2 years.
  • Drug: Dalpiciclib 100mg — Dalpiciclib: 100 mg, once daily, taken at approximately the same time every day, fasting 1 hour before and after taking the drug, for 21 consecutive days, followed by 7 days off, 28 days as a treatment cycle. It was administered for 3 years.
  • Drug: Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen — Endocrine therapy: endocrine therapy drugs selected by the investigator, including aromatase inhibitors (AIs), fulvestrant, tamoxifen, toremifene, etc.

Primary Outcomes

  • 3-year invasive disease-free survival (Observed from enrollment through 3 years.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-01-21
Completion: 2032-06-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 2000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fujian Cancer Hospital
Contact Information
Study Contact:
Chuangui Song, doctor
13960709993
songcg1971@outlook.com
Chuangui Song, doctor
13960709993
songcg1971@outlook.com
Fujian Cancer Hosptial
Ting Luo, doctor
18602866299
tina621@163.com
West China Hospital of Sichuan University
Interventions
  • Drug: Dalpiciclib 125mg — Dalpiciclib: 125 mg, once daily, taken at approximately the same time every day, fasting 1 hour before and after taking the drug, for 21 consecutive days, followed by 7 days off, 28 days as a treatment cycle. It was administered for 2 years.
  • Drug: Dalpiciclib 100mg — Dalpiciclib: 100 mg, once daily, taken at approximately the same time every day, fasting 1 hour before and after taking the drug, for 21 consecutive days, followed by 7 days off, 28 days as a treatment cycle. It was administered for 3 years.
  • Drug: Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen — Endocrine therapy: endocrine therapy drugs selected by the investigator, including aromatase inhibitors (AIs), fulvestrant, tamoxifen, toremifene, etc.
Study Locations (2 sites)
Fujian Cancer Hosptial, Fuzhou, Fujian 350001 China
West China Hospital of Sichuan University, Chengdu, Sichuan 618099 China
Eligibility Criteria
Inclusion Criteria: 1. Female aged 18 years or older with breast cancer who are postmenopausal or premenopausal/perimenopausal. 2. Patients with early-stage breast cancer whose HR status is positive and HER2 status is negative, as confirmed by histology (immunohistochemistry showing ER ≥10% and/or PR ≥10%, HER2 0-1+ or HER2 ++ but negative by FISH or CISH testing, with no amplification). 3. Patients with histologically confirmed invasive breast cancer at clinical/pathological stages II-III. Note: For stage IIA, N1 is required, or N0 with Grade 3 or Grade 2 tumors combined with high-risk factors such as Ki-67 ≥20% or positive genetic testing (including but not limited to high-risk results in the 21-gene test). If the patient has previously received neoadjuvant therapy, the clinical stage at the time before neoadjuvant therapy must meet the above criteria. 4. Patients who have previously received or not received neoadjuvant chemotherapy or adjuvant chemotherapy are eligible to enroll. 5. The time interval from surgery to enrollment must not exceed 12 months. 6. Patients who have received radiotherapy must have recovered from the acute effects of radiotherapy, and there must be at least 14 days of washout period from the end of radiotherapy to enrollment. 7. Patients who have previously received chemotherapy must have recovered from the acute adverse effects of chemotherapy before enrollment (\[CTCAE\] grade ≤1), except for hair loss or grade 2 peripheral neuropathy.There must be a washout period of at least 21 days between the last administration of chemotherapy and enrollment in the study. 8. The Eastern Cooperative Oncology Group performance status score must be 0-1. 9. The functions of major organs must meet the following requirements: a) Blood tests: neutrophils (ANC) ≥1.5×10\^9/L; platelet count (PLT) ≥90×10\^9/L; hemoglobin (Hb) ≥90 g/L. b) Blood biochemistry tests: total bilirubin (TBIL) ≤2.5×ULN; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤1.5×ULN; alkaline phosphatase ≤2.5×ULN; blood urea nitrogen (BUN) and creatinine (Cr) ≤1.5×ULN. c) 12-lead electrocardiogram: QT interval corrected using the Fridericia method (QTcF) \< 470 ms in females (QTcF calculation formula: QTcF = QT/(RR\^1/3)). Participants must voluntarily agree to participate in the study, sign the informed consent form, demonstrate good compliance, and be willing to cooperate with follow-up assessments. Exclusion Criteria: 1. Stage IV breast cancer or recurrent/metastatic breast cancer, or inflammatory breast cancer; 2. A history of any malignant tumor, or previous receipt of anti-tumor therapy or radiotherapy for any malignant tumor, excluding cured cases of cervical carcinoma in situ, basal cell carcinoma of the skin, or squamous cell carcinoma, etc. 3. Participating in other clinical trials simultaneously; 4. Received a blood transfusion within 2 weeks prior to enrollment, or received treatments such as colony-stimulating factors; 5. Individuals with a known history of allergy to any component of this medication; 6. A history of immunodeficiency, including a positive HIV test result, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation. 7. Any history of heart disease, including: (1) angina pectoris; (2) arrhythmias that require medical treatment or are clinically significant; (3) myocardial infarction; (4) heart failure; (5) any other heart disease deemed by the study investigators to be inappropriate for participation in this trial. 8. Pregnant or lactating female patients; 9. Any other circumstances in which the researchers deem the participant unsuitable for participating in this study.
Conditions Epilepsy, Anxiety, Depression Anxiety Di...
Phase Not Applicable
Enrollment 320
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

An observational behavioural and neurophysiological study of the effects of controlled sensory stimulation (such as music, for example) on brain function

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Neuronal networks (All along the study (8 years))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-12-02
Completion: 2035-12-02
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 320 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Hospitalier St Anne
Contact Information
Study Contact:
Viviane AWASSI
+33145658486
v.awassi@ghu-paris.fr
Estelle Pruvost-Robieux, MD, PHD
+33145658189
e.pruvost@ghu-paris.fr
GHU Paris Sainte Anne
Estelle Pruvost-Robieux, MD, PHD
GHU Paris Sainte Anne
Interventions
N/A
Study Locations (1 sites)
GHU Paris Sainte Anne, Paris, 75014 France
Eligibility Criteria
Inclusion Criteria: * For patients : epilepsy * For healthy volunteers: age \> 18 yo Exclusion Criteria: * For patients and healthy volonteers : Deafness * For healthy volunteers : History of neurological conditions (including stroke, coma, epilepsy, neuro-inflammatory or neurodegenerative disease) or diagnosed cognitive impairment
Conditions Depression, Treatment Resistant Depressi...
Phase PHASE2
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Repetitive Transcranial Magnetic stimulation (rTMS) is an FDA-approved therapy for treatment resistant depression (TRD) that involves brief magnetic stimulation pulses on the dorsolateral prefrontal cortex (DLPFC) brain region. But studies of rTMS alone show remission rates of \~30%. Additionally, rTMS has not been shown to improve cognitive functioning that may be an independent factor predicting treatment success. This study will develop a novel multimodal treatment, which combines intermittent theta burst stimulation (iTBS) - a type of rTMS with digital mindfulness training to engage brain plasticity, enhance cognition and alleviate depression symptoms in individuals with TRD.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Combination Product: Medi-TBS — The multimodal intervention involves combining FDA-approved repetitive transcranial magnetic stimulation (rTMS) with digital mindfulness exercises.

Primary Outcomes

  • Change in EEG source localized pDMN alpha activity (4 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-05-01
Completion: 2029-04-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, San Diego
Contact Information
Study Contact:
Jyoti Mishra, PhD
858-232-2855
braine@ucsd.edu
Jyoti Mishra, PhD
8582322855
braine@ucsd.edu
UC San Diego Health Psychiatry
Interventions
  • Combination Product: Medi-TBS — The multimodal intervention involves combining FDA-approved repetitive transcranial magnetic stimulation (rTMS) with digital mindfulness exercises.
Study Locations (1 sites)
UC San Diego Health Psychiatry, San Diego, California 92037 United States
Eligibility Criteria
Inclusion Criteria: * Diagnosis of major depressive episode (MDE, in accordance with the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5), in the context of unipolar major depressive disorder. * At least one failed antidepressant medication trial at level 3 in the Antidepressant -Treatment History Form: Short Form (ATHF-SF) classification. * Montgomery-Åsberg Depression Rating Scale (MADRS) Score \>19 (moderate - severe depression). * No increase or initiation of new antidepressant therapy in the four weeks prior to screening. * Demonstrated capacity to give informed consent. Exclusion Criteria: * Inability to provide informed consent. * Medically unstable patients. * Concomitant neurological disorder or a history of a seizure disorder. * Exhibiting current suicidal behavior rating on the Columbia Suicide Severity Rating Scale (C-SSRS) * Patients who are pregnant or breastfeeding. * Any psychotic disorder or current active psychotic symptoms. * Patients who have intracranial implants, other medical device or condition deemed unsafe for TMS. * Contraindication to MRI scanning.
Conditions Emotional Intelligence, Anxiety, Depress...
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The present study examined the effects of an emotional intelligence (EI)-based training program on emotional intelligence and mental health outcomes among secondary school teachers and students in Dhaka City, Bangladesh. The study addressed whether the EI-based intervention improves emotional intelligence and reduces psychological distress, including anxiety and depression, while enhancing overall wellbeing (emotional, social, and psychological). A quasi-experimental design was employed, comparing participants who received a structured EI training program with a control group. The intervention was based on Goleman's mixed model of emotional intelligence, focusing on four core domains: self-awareness, self-management, social awareness, and relationship management. Participants were assessed at multiple time points using standardized measures of emotional intelligence, anxiety, depression, and mental health continuum. The study also incorporated a follow-up assessment to examine outcomes over time. The findings aim to contribute to understanding the role of emotional intelligence in promoting mental health and to inform school-based psychological intervention strategies.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Enhancing Emotional Intelligence — A structured, evidence-based Emotional Intelligence (EI) training program was developed using Goleman's mixed model, focusing on self-awareness, self-management, social awareness, and relationship management. The manual was culturally adapted for Bangladesh and refined through expert review and pilot testing. The intervention was delivered over four weeks for students (one 2.5-3 hour session per week) and two intensive days for teachers (two sessions per day, \~150 minutes each). Interactive methods included lectures, group discussions, role-plays, reflective exercises, and homework tasks to enhance EI skills and real-life application. The program aimed to improve emotional competencies and psychological wellbeing among participants.

Primary Outcomes

  • Mental Health Continuum-Short Form (MHC-SF) (Baseline, immediately post-intervention, and 6-month follow-up)
  • Trait Emotional Intelligence Questionnaire - Short Form (TEIQue-SF) (Baseline, post-intervention (immediately after training), and 6-month follow-up)
  • Beck Anxiety Inventory (BAI) (Baseline, post-intervention, and 6-month follow-up)
  • Beck Anxiety Inventory for Youth (BAI-Y) (Baseline, post-intervention, and 6-month follow-up)
  • Beck Depression Inventory (BDI-II) (Baseline, post-intervention, and 6-month follow-up)
  • Beck Depression Inventory for Youth (BDI-Y) (Baseline, post-intervention, and 6-month follow-up)
  • Trait Emotional Intelligence Questionnaire - Adolescent Short Form (TEIQue-ASF) (Baseline, immediately post-intervention, and 6-month follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-30
Completion: 2026-09
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: true
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Dhaka
Principal Investigators:
  • Jannatul Ferdous (PRINCIPAL_INVESTIGATOR) - Assistant Professor, Department of Psychology, Jagannath University, Bangladesh
Contact Information
Study Contact:
Jannatul Ferdous
+880 1796640634
jannatul.psy.jnu@gmail.com
Jannatul Ferdous
+880 1796640634
jisan0391@gmail.com
Secondary Schools (Bangla Medium), Dhaka City
jisan0391@gmail.com
Secondary Schools (Bangla Medium), Dhaka City
Interventions
  • Behavioral: Enhancing Emotional Intelligence — A structured, evidence-based Emotional Intelligence (EI) training program was developed using Goleman's mixed model, focusing on self-awareness, self-management, social awareness, and relationship management. The manual was culturally adapted for Bangladesh and refined through expert review and pilot testing. The intervention was delivered over four weeks for students (one 2.5-3 hour session per week) and two intensive days for teachers (two sessions per day, \~150 minutes each). Interactive methods included lectures, group discussions, role-plays, reflective exercises, and homework tasks to enhance EI skills and real-life application. The program aimed to improve emotional competencies and psychological wellbeing among participants.
Study Locations (1 sites)
Secondary Schools (Bangla Medium), Dhaka City, Dhaka, 1100 Bangladesh
Eligibility Criteria
Inclusion Criteria: * Participants include secondary school students aged 12-17 years and secondary school teachers aged 22-60 years. 1. students (both boys and girls) enrolled in Classes 7 to 10 in coeducational Bangla-medium secondary schools in Dhaka city; 2. teachers (male and female) who taught in these classes; 3. teachers who provided informed consent to participate in the training; 4. students who provided assent along with parental consent; 5. Students identified as belonging to lower EI profiles (e.g., emotionally vulnerable or at-risk groups) based on latent profile analysis (LPA) of Trait Emotional Intelligence scores; and 6. individuals who expressed willingness to actively participate in the study. \- Exclusion Criteria: <!-- --> 1. individuals with a reported history of severe mental illness; 2. individuals with identifiable visual, hearing, or physical impairments that could interfere with participation in the program; 3. teachers and students from English-medium or English-version schools; 4. individuals unwilling or unable to provide voluntary informed consent/assent or to complete the full program; 5. those who had previously attended any emotional intelligence training program; and 6. Students identified as belonging to higher EI profiles (e.g., emotionally competent or well-adjusted groups) based on latent profile analysis (LPA) of Trait Emotional Intelligence scores. \-
Conditions Anxiety, Stress, Depression Disorder, Qu...
Phase NA
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The experience of infertility can cause significant emotional instability, especially for patients awaiting In Vitro Fertilization (IVF) treatment, generating anxiety, stress, and depressive symptoms. This study is a randomized clinical trial assessing the effectiveness of aromatherapy in improving mental health and quality of life in women undergoing infertility treatment. 120 participants will be randomized into three groups (Intervention, Placebo, and Control). The intervention involves the inhalation of true lavender essential oil (Lavandula angustifolia) for four weeks.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Other: Lavender essential oil Inhalation — The inhalation of lavender essential oil will be performed twice a day, preferably upon waking and before nighttime sleep. Participants will be instructed to settle into a quiet environment, lying down or sitting, to consciously perform the inhalation. The procedure consists of opening the inhaler, positioning it approximately 1cm from the nostrils, and beginning the inhalation through habitual breaths.The protocol stipulates that each inhalation session lasts 15 minutes, which can be timed on the participant's own cell phone. After the inhalation is finished, the inhaler should be kept closed. To facilitate monitoring and ensure adherence to the protocol, participants will receive a weekly schedule to record completed sessions and will be encouraged to keep an aromatherapy diary to record their perceptions and feelings throughout the study, providing qualitative data that will contribute to analyzing the effect of the practice on the well-being of women undergoing fertility treatment.
  • Other: Synthetic lavender aroma inhalation — The inhalation of synthetic lavender essence will be performed twice a day, preferably upon waking and before bedtime. Participants will be instructed to find a quiet environment, lying down or sitting, to consciously perform the inhalation. The procedure consists of opening the inhaler, positioning it approximately 1 cm from the nostrils, and beginning the inhalation through habitual breaths. The protocol stipulates that each inhalation session should last 15 minutes, and the time can be timed on the participant's cell phone. After the inhalation is finished, the inhaler should be kept closed. To facilitate monitoring and ensure adherence to the protocol, participants will receive a weekly schedule to mark completed sessions and will be encouraged to keep an aromatherapy diary to record their perceptions and feelings throughout the study, providing qualitative data that will contribute to the analysis of the practice's effect on the well-being of women undergoing fertility treatment.

Primary Outcomes

  • Change from Baseline in Depression, Anxiety, and Stress Scale (DASS-21) Scores (Baseline (Time 0), Week 4 (Time 1, end of Intervention) and Week 8 (Time 2, 4 weeks post-intervention))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-01
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Federal University of Minas Gerais
Principal Investigators:
  • Bárbara P Aquino, MSc (STUDY_CHAIR) - Federal University of Minas Gerais
  • Jhenifer K Rodrigues, PhD (PRINCIPAL_INVESTIGATOR) - POTENTIA - Technical, therapeutic, and human development consulting and advisory services
  • Rubens L C Tavares, MD, PhD (PRINCIPAL_INVESTIGATOR) - Federal University of Minas Gerais
Contact Information
Study Contact:
Rubens L C Tavares, MD, PhD
+55 31 3409-9764
rubens.ufmg@gmail.com
Bárbara P Aquino, MSc
babiaquino.aromaterapia@gmail.com
Rubens L C Tavares, MD, PhD
rubens.ufmg@gmail.com
Department of Obstetrics and Gynecology - Federal University of Minas Gerais - Brazil
Interventions
  • Other: Lavender essential oil Inhalation — The inhalation of lavender essential oil will be performed twice a day, preferably upon waking and before nighttime sleep. Participants will be instructed to settle into a quiet environment, lying down or sitting, to consciously perform the inhalation. The procedure consists of opening the inhaler, positioning it approximately 1cm from the nostrils, and beginning the inhalation through habitual breaths.The protocol stipulates that each inhalation session lasts 15 minutes, which can be timed on the participant's own cell phone. After the inhalation is finished, the inhaler should be kept closed. To facilitate monitoring and ensure adherence to the protocol, participants will receive a weekly schedule to record completed sessions and will be encouraged to keep an aromatherapy diary to record their perceptions and feelings throughout the study, providing qualitative data that will contribute to analyzing the effect of the practice on the well-being of women undergoing fertility treatment.
  • Other: Synthetic lavender aroma inhalation — The inhalation of synthetic lavender essence will be performed twice a day, preferably upon waking and before bedtime. Participants will be instructed to find a quiet environment, lying down or sitting, to consciously perform the inhalation. The procedure consists of opening the inhaler, positioning it approximately 1 cm from the nostrils, and beginning the inhalation through habitual breaths. The protocol stipulates that each inhalation session should last 15 minutes, and the time can be timed on the participant's cell phone. After the inhalation is finished, the inhaler should be kept closed. To facilitate monitoring and ensure adherence to the protocol, participants will receive a weekly schedule to mark completed sessions and will be encouraged to keep an aromatherapy diary to record their perceptions and feelings throughout the study, providing qualitative data that will contribute to the analysis of the practice's effect on the well-being of women undergoing fertility treatment.
Study Locations (1 sites)
Department of Obstetrics and Gynecology - Federal University of Minas Gerais - Brazil, Belo Horizonte, Minas Gerais 30130-100 Brazil
Eligibility Criteria
Inclusion Criteria: * Female gender, age over 18 years. * Diagnosis of infertility with indication for In Vitro Fertilization (IVF). * Patients on the waiting list at HC-UFMG. * Agreement not to practice other mind-body or herbal complementary therapies during the study. * DASS-21 screening score compatible with at least mild anxiety, stress, and/or depression. * No aversion to inhaling essential oil or synthetic lavender essence. Exclusion Criteria: * Severe neurological, psychiatric, or clinical disorders (e.g., schizophrenia, severe depression) that prevent participation. * Use of medications that could confound the primary outcome (e.g., sleep medications, anxiolytics, antidepressants, neuroleptics) in the 30 days prior to or during the study. * Known allergy to lavender products. * Pregnancy during the study period. * Use of essential oils in the last 90 days.
Conditions Breast Cancer Stages I, Breast Cancer St...
Phase NA
Enrollment 96
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate the potential supportive effects of rice bran arabinoxylan compound (Biobran) in patients with breast cancer receiving paclitaxel and doxorubicin chemotherapy. The study will assess chemotherapy-related side effects, quality of life, tumor size, tumor antigens, and routine blood test parameters over 24 weeks of treatment.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Double

Interventions / Regimen

  • Dietary Supplement: Biobran supplementation — 3 g Biobran per day for 24 weeks

Primary Outcomes

  • Change from baseline in the mean quality of life score at 12 weeks (Baseline and at 6、12、18、24 weeks after chemotherapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-07
Completion: 2026-08-31
Eligibility
Age: 20 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 96 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: China Medical University Hospital
Contact Information
Study Contact:
Chong-Kuei Lii, PhD
+886916226551
cklii@mail.cmu.edu.tw
Yi-Chen Huang, PhD
886915754860
yichenhuang@mail.cmu.edu.tw
Chong Kuei Lii
886-222053366
cklii@mail.cmu.edu.tw
China Medical University Hospital
Interventions
  • Dietary Supplement: Biobran supplementation — 3 g Biobran per day for 24 weeks
Study Locations (2 sites)
China Medical University Hospital, Taichung, 406040 Taiwan
China Medical University, Taichung, 406040 Taiwan
Eligibility Criteria
Inclusion Criteria: * Breast cancer stage I-III Exclusion Criteria: * pregnant, lactation, breast recurrence, mental disease, autoimmune disease over hte past 5 years, people who take plant or fungal polysaccharide health supplements
Conditions Healthy Participants, Anxiety Disorders ...
Phase NA
Enrollment 104
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study investigates if anhedonia and anxiety symptoms are associated with alterations in reinforcement learning, effort trade-offs for wins vs. punishments, and foraging behavior under threat. Moreover, it will investigate whether these processes can be influenced by a metabolic load and/or transcutaneous vagus nerve stimulation (tVNS). The project consists of (a) an online reinforcement learning study, used to characterize learning, reward sensitivity, and meta-cognition, and (b) a laboratory study in which participants first undergo fMRI while completing an effort-based decision-making task. Second, participants will complete two sessions in VR with randomized active or sham tVNS during a foraging task before and after a caloric load with concurrent physiological recordings.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Single

Interventions / Regimen

  • Device: tVNS — The intervention consists of event-triggered tVNS in the form of short pulses (\~1-5s; frequency: 25Hz). A non-CE-certified and non-medical device (tVNS® R tVNS technologies, for research purposes) will be used. Stimulation intensity will be individually calibrated to ensure perceptible (mild pricking) but non-painful stimulation for each participant. The protocol is the same for all groups.
  • Device: Sham — The sham condition similarly consists of event-triggered, closed-loop stimulation, but without vagus nerve activation (short pulses of 1-5s; frequency: 25Hz). A non-CE-certified and non-medical device (tVNS® R, for research purposes) will be used. The manufacturer is not involved in the study. Stimulation intensity will be individually calibrated to ensure perceptible (mild pricking) but non-painful stimulation for each participant. The protocol is the same for all groups.

Primary Outcomes

  • Stimulation-induced changes in the number of rewards collected under threat (VR foraging task) (During each stimulation session (tVNS and sham) throughout study completion (approximately 3 weeks))
  • BOLD response during the effort-trade-off task (offer-phase) (Collected during fMRI session (single session throughout study completion ~35min per participant))
  • Reward learning (Online task performance assessed online before lab-visits (approximately 10 days))
  • Metabolic state x stimulation-induced changes in the number of rewards collected under threat (VR task) (During each stimulation session (tVNS and sham) throughout study completion (approximately 3 weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-23
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 104 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Dr. Nils B. Kroemer
Collaborators: University of Bonn, Else Kröner Fresenius Foundation
Contact Information
Study Contact:
Dr. Anne Kühnel
+49 228 28711519
akuehnel@uni-bonn.de
Prof. Dr. rer. nat. Nils Kroemer
+49 228 28719123
nkroemer@uni-bonn.de
University Hospital Bonn, Bonn, Germany
Interventions
  • Device: tVNS — The intervention consists of event-triggered tVNS in the form of short pulses (\~1-5s; frequency: 25Hz). A non-CE-certified and non-medical device (tVNS® R tVNS technologies, for research purposes) will be used. Stimulation intensity will be individually calibrated to ensure perceptible (mild pricking) but non-painful stimulation for each participant. The protocol is the same for all groups.
  • Device: Sham — The sham condition similarly consists of event-triggered, closed-loop stimulation, but without vagus nerve activation (short pulses of 1-5s; frequency: 25Hz). A non-CE-certified and non-medical device (tVNS® R, for research purposes) will be used. The manufacturer is not involved in the study. Stimulation intensity will be individually calibrated to ensure perceptible (mild pricking) but non-painful stimulation for each participant. The protocol is the same for all groups.
Study Locations (1 sites)
University Hospital Bonn, Bonn, Germany, Bonn, 53127 Germany
Eligibility Criteria
Inclusion Criteria: * BMI between 18,5 and 30,0 kg/m2, * between 18 and 40 years of age, and * be able and willing to provide informed consent. Exclusion Criteria: * have a high risk of suicide, * have a lifetime diagnosis of severe neurological disorder (incl. ADHD), schizophrenia, bipolar disorder, or severe substance abuse, posttraumatic stress disorder, obsessive-compulsive disorder, diabetes, epilepsy, or coronary heart disease * have fulfilled criteria for an eating disorder or somatic symptom disorder within the last 12-months, * take medication (except psychopharmacological medication for MDD or anxiety), patients have to be on stable psychopharmacological medication for at least two months before study participation (minimizing confounding effects) * contraindications for MRI (metal implants or claustrophobia) * for female individuals if they are pregnant or nursing at the time, * impaired movement ability or hearing * impaired, uncorrected vision (need contact lenses) * contraindications for tVNS hearing aids or diseased skin on the right ear.

Neutralizing Interleukin (IL)-6

NCT07493317
Recruiting
Conditions Major Depressive Disorder
Phase PHASE2
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The proposed study aims to establish the feasibility and safety of subcutaneous tocilizumab, a monoclonal antibody (mAb) against interleukin (IL)-6 receptor, in adults with Major Depressive Disorder (MDD) and evidence of peripheral immune activation. IL-6 is a pro-inflammatory cytokine implicated in the pathophysiology of depression. The investigators hypothesize that neutralizing peripheral immune signaling via IL-6 receptor blockade with tocilizumab will improve neural and behavioral measures of reward processing. This is an open-label, proof-of concept, trial in which up to N=20 adults with MDD meeting a specific immune enrichment criterion will receive open-label tocilizumab over 8 weeks. A healthy control (HC) group (N=20) will undergo baseline neuroimaging and blood-based biomarker assessment without receiving the study drug to aid interpretation of findings. Blood-based immune markers and brain MRI scans (including task-based reward activation and resting-state functional connectivity) will be assessed at baseline for all participants and again post treatment for the MDD group.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Tocilizumab — One treatment condition in an open-label study design: subcutaneous injection of tocilizumab 162 mg at weeks 0, 2, 4, 6, and 8.

Primary Outcomes

  • Change in ventral stratal activation during reward processing (fMRI) (at week 0 and week 10)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-03-26
Completion: 2031-02-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Icahn School of Medicine at Mount Sinai
Principal Investigators:
  • James Murrough (PRINCIPAL_INVESTIGATOR) - Icahn School of Medicine at Mount Sinai
Contact Information
Study Contact:
Alexia Lizzano
3322437059
alexia.lizzano@mssm.edu
Mackenzie Hargrove
3322437052
mackenzie.brown@mssm.edu
Mackenzie Hargrove
332-243-7052
mackenzie.brown@mssm.edu
Icahn School of Medicine at Mount Sinai
Interventions
  • Drug: Tocilizumab — One treatment condition in an open-label study design: subcutaneous injection of tocilizumab 162 mg at weeks 0, 2, 4, 6, and 8.
Study Locations (1 sites)
Icahn School of Medicine at Mount Sinai, New York, New York 10029 United States
Eligibility Criteria
Inclusion Criteria: For MDD participants: * Written informed consent; * Ability to comply with the requirements of the study as determined by the PI; * Ages 18-70 years; * Any gender; * DSM-5 diagnosis of MDD in a current Major Depressive Episode; * Immune enrichment criterion: elevated monocyte count ≥ 500 cells/μL at screening; * If patient is on antidepressant medication, they must be on a stable dose for ≥4 weeks prior to treatment; * SHAPS score ≥20 * If female of childbearing potential, must agree to use of a medically accepted form of contraception, or else agree to abstinence until 6 months after the last dose of study drug; * Male patients, if heterosexually active with a partner who is female of childbearing potential, pregnant, or breastfeeding, must agree to barrier contraception for the treatment period and for at least 6 months after the last dose of the study drug. Female partners of male participants must use at least one form of highly effective contraception starting at least one cycle prior to male patient study drug initiation until 6 months after the last dose of study drug. * Meet all MRI safety criteria. For Healthy Volunteers: * Written informed consent; * Ability to comply with the requirements of the study as determined by the PI; * Ages 18-70 * Any gender; * No current or past DSM-5 psychiatric disorder; * Meet all MRI safety criteria. Exclusion Criteria: For MDD Participants * A primary DSM-5 psychiatric diagnosis other than MDD, with the exception of comorbid anxiety disorders (including agoraphobia, generalized anxiety disorder, social anxiety disorder, panic disorder) and post-traumatic stress disorder, which are permitted. * History of schizophrenia, schizoaffective disorder, other psychotic disorder, MDD with psychotic features, or bipolar I or II disorder. * Diagnosis of a major neurocognitive disorder. * Moderate or severe substance use disorder within the past 6 months (excluding nicotine use disorder). * Positive urine toxicology screen for illicit substances at screening. * Serious or imminent risk of self-harm or violence, as determined by the PI, including: * Suicide attempt within the past 2 years, or * C-SSRS ideation score \>2 within the past month. * Any contraindication to MRI, including claustrophobia, retained metallic foreign bodies, magnetic implants or pacemakers, or inability to tolerate MRI procedures. * Clinically significant abnormalities on physical examination or laboratory testing. * Unstable or clinically significant medical illness, including but not limited to hepatic, renal, gastrointestinal, respiratory, cardiovascular (including ischemic heart disease), endocrine, neurologic (including history of severe head injury), immunologic, or hematologic conditions. * Evidence of active or untreated infection, including * Active tuberculosis (TB) or untreated latent TB * Positive QuantiFERON-TB Gold test at screening * Known HIV infection * Active Hepatitis B or Hepatitis C infection * Current or recent (within an appropriate washout period) use of biologic therapies or other immunosuppressive agents (PRN NSAIDs permitted). * Known hypersensitivity to tocilizumab or its excipients. * Receipt of a live or live-attenuated vaccine within 30 days prior to first dose, or planned receipt during the study period. * Pregnancy, breastfeeding, or unwillingness to use effective contraception during the study and for 6 months after the last dose. * Any condition that, in the opinion of the PI, would compromise participant safety or data integrity. For Healthy Volunteers * Any current or unstable medical illness, including hepatic, renal, gastrointestinal, respiratory, cardiovascular (including ischemic heart disease), endocrine, neurologic (including history of severe head injury), immunologic, or hematologic disease. * Use of biologic therapies or immunosuppressive agents (PRN NSAIDs permitted). * Positive urine toxicology screen for illicit substances at screening. * Pregnancy at the time of baseline assessments (e.g., MRI).